Benefits
Stress and anxiety in healthy volunteers
A double-blind placebo-controlled trial in healthy volunteers showed multi-domain psychological benefits over 30 days at 3 billion CFU daily — improvements on global anxiety, somatization, depression, and anger-hostility scales. 24-hour urinary cortisol was significantly reduced, providing endocrine evidence beyond self-report.
Anxiolytic-like effects in animal models
Animal experiments using a defensive burying anxiety test showed reductions in anxiety-like behavior with effect sizes comparable to diazepam. Preclinical evidence with a benzodiazepine comparator — supporting the gut-brain anxiolytic mechanism.
Subgroup confirmatory analysis
Follow-up analysis confirmed reduced anxiety and depression scale scores over 30 days. Subgroup analysis in individuals with lower baseline cortisol provided confirmatory evidence for the cortisol-modulation mechanism.
Stress-related GI discomfort
Earlier clinical evidence shows reduced stress-induced GI discomfort with this strain combination. Supports the bidirectional gut-brain positioning — addressing both psychological symptoms and GI manifestations of stress.
Brain-imaging mechanism evidence
An fMRI study using a related Lallemand formulation (with an added L. plantarum strain) during stress task showed measurable brain-effect signals. Different formulation but same R0052/R0175 strain pair — proof-of-concept brain imaging support.
Stress study in medical students
An 8-week stress study in medical students using the strain combination has recently completed. Outcome data publication awaited; reflects ongoing contemporary research into real-world stress applications.
Honest counter-evidence in clinical depression
A double-blind randomized trial in clinical depression found no significant difference between the probiotic and placebo on psychological outcomes or blood biomarkers. Important honest counter-evidence: clinical depression may not respond as the healthy-volunteer stress populations do. Use for stress and mild anxiety, not as depression treatment.
Mechanism of action
GABAergic anxiolytic activity (preclinical, diazepam-like)
Preclinical evidence indicates GABA-mediated effects underlying the anxiolytic activity — supporting the diazepam-like effect size in the conditioned defensive burying test (Messaoudi 2010 rats). Mechanistic basis for stress and anxiety effects.
HPA axis cortisol attenuation
24-hour urinary free cortisol reduction in Messaoudi 2010 — measurable HPA axis modulation. Quantitative endocrine evidence beyond self-report scales.
Vagal afferent signaling
Gut-to-brain communication via vagal afferents is a proposed psychobiotic mechanism. Strain-specific vagal signaling effects have been demonstrated for both R0052 and R0175 in preclinical work.
Short-chain fatty acid production
Both strains produce short-chain fatty acids that influence enteric and central nervous system function via GPR41/GPR43 receptors and direct effects on gut barrier function.
Tryptophan / serotonin precursor modulation
Modulation of intestinal tryptophan metabolism may influence systemic serotonin precursor availability — one of several proposed gut-brain axis pathways for psychobiotic effects.
Gut barrier integrity and reduced systemic inflammation
Both strains support tight junction integrity and reduce LPS translocation. Lower systemic inflammation can improve mood and cognitive function via reduced neuroinflammation.
Synergistic two-strain combination
Effects appear stronger with the R0052 + R0175 combination than either strain alone, suggesting complementary mechanisms. The pivotal evidence base is for the combination — single-strain data does not transfer directly.
Clinical trials
Messaoudi M et al. 2010 (Br J Nutr 105:755-764, doi:10.1017/S0007114510004319). Double-blind placebo-controlled randomized parallel-group study in healthy volunteers, 30 days at 3×10⁹ CFU/day. Multi-domain benefits on HSCL-90, HADS, Coping Checklist; 24-hour urinary free cortisol reduced. Rat experiments showed diazepam-like anxiolytic effects in conditioned defensive burying test. The pivotal trial defining the ingredient's stress and anxiety positioning.
Messaoudi M et al. 2011 (Gut Microbes 2(4):256-261). 30-day combination decreased HADS and HSCL-90 global severity index. Subgroup analysis (n=25 with baseline urinary free cortisol <50 ng/mL) — confirmatory evidence in low-baseline-cortisol subgroup.
Romijn AR et al. 2017 (Aust N Z J Psychiatry). Double-blind randomized placebo-controlled trial in clinical depression. No significant difference between probiotic and placebo on any psychological outcome (Cohen's d 0.07-0.16). No blood biomarker differences. Important honest counter-evidence — clinical depression does not respond like healthy-volunteer stress.